Afatinib Withdrawn Phase 2 Trials for Lung Cancers Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01480141A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)